To evaluate the efficacy of pharmaceutical-grade cannabidiol (CBD) in reducing seizures and co-morbid anxiety symptoms in pediatric epilepsy, and to examine changes in circulating endocannabinoids and related lipid biomarkers pre- and post-treatment.
No takes yet. Share an insight, caveat, or question.
Hopkins et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: